Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial Randomized trials had shown that rituximab maintenance (RM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results